产品描述: | MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs |
靶点: |
MMP-9;MMP |
体外研究: |
MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity.
MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells. |
体内研究: |
MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor.
MMP-9-IN-1 inhibits cancer cell metastasis in vivo. Animal Model: 4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor Dosage: 20 mg/kg Administration: Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks, Result: Resulted in a profound delay in tumor growth. Inhibited cancer cell metastasis. |
参考文献: |
1. Dufour A, et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 2011 Jul 15;71(14):4977-88.
2. Alford VM, Kamath A, Ren X, et al. Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions. ACS Chem Biol. 2017;12(11):2788-2803. |
溶解性: |
Soluble in DMSO |
保存条件: |
2-8℃ |
配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
1 mM |
2.707 ml |
13.536 ml |
27.072 ml |
5 mM |
0.541 ml |
2.707 ml |
5.414 ml |
10 mM |
0.271 ml |
1.354 ml |
2.707 ml |
50 mM |
0.054 ml |
0.271 ml |
0.541 ml |
|
注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |